These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 21864036)
1. The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma. Andresen S; Brandt J; Dietrich S; Memmer ML; Ho AD; Witzens-Harig M Leuk Lymphoma; 2012 Mar; 53(3):386-93. PubMed ID: 21864036 [TBL] [Abstract][Full Text] [Related]
2. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386 [TBL] [Abstract][Full Text] [Related]
3. Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy. Brandt J; Dietrich S; Meissner J; Neben K; Ho AD; Witzens-Harig M Leuk Lymphoma; 2010 Nov; 51(11):2012-20. PubMed ID: 20858092 [TBL] [Abstract][Full Text] [Related]
4. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience. Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847 [TBL] [Abstract][Full Text] [Related]
5. Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. Derenzini E; Casadei B; Broccoli A; Gandolfi L; Pellegrini C; Zinzani PL Br J Haematol; 2014 Aug; 166(4):625-8. PubMed ID: 24750128 [No Abstract] [Full Text] [Related]
6. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W; Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325 [TBL] [Abstract][Full Text] [Related]
8. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097 [TBL] [Abstract][Full Text] [Related]
9. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Jäeger G; Neumeister P; Brezinschek R; Höfler G; Quehenberger F; Linkesch W; Sill H Eur J Haematol; 2002 Jul; 69(1):21-6. PubMed ID: 12270058 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390 [TBL] [Abstract][Full Text] [Related]
11. Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. Illidge TM; McKenzie HS; Mayes S; Bates A; Davies AJ; Pettengell R; Stanton L; Cozens K; Hampson G; Dive C; Zivanovic M; Tipping J; Gallop-Evans E; Radford JA; Johnson PW Br J Haematol; 2016 Apr; 173(2):274-82. PubMed ID: 26849853 [TBL] [Abstract][Full Text] [Related]
12. Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL. Fisher RI Clin Adv Hematol Oncol; 2005 Jul; 3(7):544-6. PubMed ID: 16167036 [No Abstract] [Full Text] [Related]
13. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276 [TBL] [Abstract][Full Text] [Related]
14. Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma. McClanahan F; Hielscher T; Rieger M; Hensel M; Bentz M; Schmidt-Wolf I; Käbisch A; Salwender H; Dürk H; Staiger H; Mandel T; Neben K; Hillengass J; Leo E; Krämer A; Ho AD; Witzens-Harig M Am J Hematol; 2012 Oct; 87(10):E68-71. PubMed ID: 22847344 [No Abstract] [Full Text] [Related]
16. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W; Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739 [TBL] [Abstract][Full Text] [Related]
17. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. Chen YB; Hochberg EP; Feng Y; Neuberg D; Rawal B; Motyckova G; Fisher DC; McAfee SL; Spitzer TR; Lacasce AS Leuk Lymphoma; 2010 May; 51(5):789-96. PubMed ID: 20367136 [TBL] [Abstract][Full Text] [Related]
18. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058 [TBL] [Abstract][Full Text] [Related]
19. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Jacobsen E; Freedman A Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900 [TBL] [Abstract][Full Text] [Related]
20. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + 1-131 tositumomab for newly diagnosed follicular non-Hodgkin lymphoma. Clin Adv Hematol Oncol; 2006 Jul; 4(7):536-8. PubMed ID: 17147240 [No Abstract] [Full Text] [Related] [Next] [New Search]